GlassScriptPhysician profile
Rose N Eskin
NPI 1821078957
$1,347.62
in general payments reported to CMS, 2019-2025
19 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $74.13 · 2021: $55.48 · 2022: $125 · 2023: $326 · 2024: $328 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $286.37 | 2019-2024 | |
| Coopersurgical, INC. | $254.33 | 2019-2024 | Endosee |
| Astellas Pharma US INC | $174.40 | 2023-2024 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $101.42 | 2024 | Injectafer |
| Amgen INC. | $95.54 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $86.57 | 2019-2024 | |
| Allergan, INC. | $61.09 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $44.57 | 2025 | Myfembree, Gemtesa |
| Avion Pharmaceuticals | $40.56 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $40.07 | 2023 | |
| Exact Sciences Corporation | $31.38 | 2025 | The Cologuard Plus Collection Kit |
| Millicent US INC | $24.35 | 2025 | Intrarosa, Femring |
| Sage Therapeutics, LLC | $23.50 | 2025 | Zurzuvae |
| Lilly USA, LLC | $15.02 | 2025 | Zepbound |
| Hologic Sales and Service, LLC | $15.00 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $13.49 | 2019 | |
| Therapeuticsmd, INC. | $13.41 | 2019 | |
| Pharmacosmos Therapeutics INC. | $13.32 | 2024 | Monoferric |
| Amag Pharmaceuticals, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Eskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.